Trials / Completed
CompletedNCT00519324
Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer
A Single Arm, Multi-center Phase II Study of RAD001 in Patients With Advanced Gastric Carcinoma Whose Cancer Has Progressed Despite Prior Treatment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of everolimus 10mg daily in patients with advanced gastric carcinoma (inoperable, recurrent or metastatic gastric cancer) whose cancer has progressed despite prior treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus | 10 mg/day (2 tablets of 5 mg each) |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2009-01-01
- First posted
- 2007-08-22
- Last updated
- 2016-11-18
Locations
8 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00519324. Inclusion in this directory is not an endorsement.